Enveric Biosciences (ENVB) Common Equity (2010 - 2026)
Enveric Biosciences (ENVB) posted Common Equity of $5.1 million for Q1 2026, up 21.14% sequentially from $4.2 million in Q4 2025, and up 29.18% YoY from $3.9 million in Q1 2025.
Enveric Biosciences (ENVB) Common Equity (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Common Equity for 17 years, with the latest figure at $5.1 million in Q1 2026.
- Quarterly Common Equity rose 29.18% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (up 29.18% YoY) and the FY2025 annual result came in at $4.2 million, up 162.28% from the prior year.
- Common Equity improved to $5.1 million in Q1 2026 per ENVB's latest filing, from $4.2 million in the prior quarter.
- Over five years, Common Equity peaked at $24.4 million in Q1 2022 and troughed at $1.6 million in Q4 2024.
- A 5-year average of $8.2 million and a median of $4.9 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2025: Common Equity plunged 89.34% in 2023, then soared 162.28% in 2025.
- Over 5 years, Common Equity stood at $14.7 million in 2022, then sank by 86.67% to $2.0 million in 2023, then decreased by 18.58% to $1.6 million in 2024, then jumped by 162.28% to $4.2 million in 2025, then increased by 21.14% to $5.1 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $5.1 million, $4.2 million, and $3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | 8.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.06 Mn |
| Dec 31, 2025 | 4.18 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Jun 30, 2025 | 2.18 Mn |
| Mar 31, 2025 | 3.92 Mn |
| Dec 31, 2024 | 1.59 Mn |
| Sep 30, 2024 | 3.95 Mn |
| Jun 30, 2024 | 5.41 Mn |
| Mar 31, 2024 | 6.48 Mn |
| Dec 31, 2023 | 1.96 Mn |
| Sep 30, 2023 | 2.44 Mn |
| Jun 30, 2023 | 4.87 Mn |
| Mar 31, 2023 | 10.41 Mn |
| Dec 31, 2022 | 14.67 Mn |
| Sep 30, 2022 | 22.84 Mn |
| Jun 30, 2022 | 21.97 Mn |
| Mar 31, 2022 | 24.44 Mn |
| Dec 31, 2021 | 22.31 Mn |
| Sep 30, 2021 | 55.37 Mn |
| Jun 30, 2021 | 18.82 Mn |